NIPPON SHINYAKU CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1919-09-23
- Employees
- 2.2K
- Market Cap
- $1.6B
A Study of Absorption, Metabolism, Excretion of [14C]-NS-580 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C] NS-580
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Nippon Shinyaku Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT06670898
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Ltd, Leeds, United Kingdom
Extension Study of NS-089/NCNP-02 in DMD
Phase 2
Active, not recruiting
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Drug: NS-089/NCNP-02
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Nippon Shinyaku Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05135663
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇯🇵National Center of Neurology and Psychiatry, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath